Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study
Vienna, Europe, June 9, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PDprotec®. In this double-blind, placebo-controlled cross-over study, the two primary endpoints were successfully met.
> read more